<DOC>
	<DOCNO>NCT00322023</DOCNO>
	<brief_summary>This study determine whether increase D-serine within body improve negative symptom cognitive impairment people schizophrenia .</brief_summary>
	<brief_title>Safety Effectiveness D-Serine Schizophrenia</brief_title>
	<detailed_description>Schizophrenia life-long brain disorder affect approximately 1 percent Americans year . Schizophrenia extremely disable , cause people hear voice , experience paranoia hallucination , believe others control thought , even fail maintain job care . Current medication help relieve symptom , . Some people schizophrenia still suffer negative symptom , difficulty talk , express emotion , motivation ; may also suffer cognitive impairment , decrease concentration memory loss . D-serine , amino acid find within body , activate brain cell receptor appear play role learn memory . This study determine whether add D-serine solution stable antipsychotic medication regimen decrease negative symptom people schizophrenia . Participants open-label study remain regular medication regimen least 2 week . During time start treatment , participant interview emotional problem , marital status , education , family background , employment history , drug alcohol problem . Participants also undergo physical exam , electrocardiogram ( EKG ) , vital sign measurement , psychological test , cognitive task , electroencephalogram ( EEG ) . Participants begin 4 week treatment D-serine . In addition participant ' regular medication regimen , drink D-serine powder mixed water twice daily . Every 2 week , participant undergo physical exam interview change symptoms emotional problem may experience . Blood urine sample take throughout study . After 4 week , participant undergo EKG , EEG , psychological test cognitive task complete prior treatment . A follow-up visit occur 2 week post-treatment monitor change negative symptom .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Structured Clinical Interview DSMIIIR diagnosis schizophrenia schizoaffective disorder PANSS 3 factor negative symptom inclusion score great 20 prior study entry PANSS total score 60 110 SimpsonAngus Scale total score 12 less Calgary Depression Inventory total score 10 suicide score le 2 No change Clinical Global Impressions ( CGI ) Scale score prior study entry Chlorpromazine ( CPZ ) equivalent 1500 less Willing use effective form birth control throughout study sexually active High extrapyramidal symptom ( EPS ) level Began , discontinue , adjust psychotropic medication within 2 week study entry Taking investigational medication within 2 week study entry Contraindication study medication Serious unstable medical illness Pregnant breastfeeding Alcohol drug abuse within 6 month study entry Diagnosed neurodegenerative disease seizure disorder History kidney impairment Currently take clozapine Currently take two antipsychotic medication Currently take stimulant cholinesterase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Negative symptom</keyword>
	<keyword>NMDA</keyword>
	<keyword>Glutamate</keyword>
	<keyword>Glycine</keyword>
</DOC>